Abbott Stock Surges 1.42% with 7.67 Billion Trading Volume Ranking 94th in Market

On April 22, 2025, Abbott's trading volume reached 7.67 billion, ranking 94th in the day's stock market. The company's stock price increased by 1.42%.

Abbott has introduced a new universal FreeStyle Libre CGM app in the U.S. This app offers a simplified view of data patterns, allowing users to better understand the impact of food, activity, and other factors on their glucose levels. The app is compatible with both FreeStyle Libre 2 and FreeStyle Libre 3 sensors, providing continuous data streaming for all users. This innovation is expected to enhance the user experience and improve the management of diabetes.

Several analysts have recently adjusted their price targets for Abbott Laboratories. Bernstein and Societe Generale raised their target to $144, while TD Cowen and RBC Capital both set their targets at $145. UBS maintained a Buy rating with a $148 price target. Piper Sandler also raised its target to $145, keeping an Overweight rating. Stifel, however, cut its target to $135 while maintaining a Buy rating. Oppenheimer and Raymond James increased their targets to $140 and $142, respectively. BTIG also raised its target to $145. These adjustments reflect the positive outlook on Abbott's performance and growth prospects.